HSBC upgraded Eli Lilly and Co (LLY) to Hold from Reduce on August 26, 2025. The stock is currently priced at $1,055.18.
This upgrade reflects a more optimistic view on Eli Lilly's prospects, suggesting improved fundamentals or enhanced confidence in the company's strategic direction. Analyst ratings, while based on research and financial models, should be considered alongside various factors including company fundamentals and industry trends.
Eli Lilly, headquartered in Indianapolis, Indiana, operates in the pharmaceuticals sector with a market capitalization of $992.3 billion. The company has a trailing twelve-month (TTM) price-to-earnings (P/E) ratio of 53.89 and an earnings per share (EPS) of 20.45. The dividend yield stands at 57.2%.
Upcoming earnings are scheduled for August 5, 2026, with an estimated EPS of $7.86 and revenue of $18.7 billion. Recent earnings performance shows a Q3 2025 EPS of $7.02, exceeding estimates by 22%.
As of November 1, 2025, the analyst consensus for Eli Lilly is categorized as Buy, with 9 Strong Buy, 18 Buy, and 9 Hold ratings among 36 analysts. This upgrade by HSBC is part of a broader trend, as various firms have maintained or adjusted their ratings in recent weeks.
Analysts' opinions can change as new information becomes available, reflecting the dynamic nature of market assessments.